

**Drug Utilization Review Board**  
(DUR Board)  
**Meeting – February 13, 2008 @ 6:00 p.m.**

Oklahoma Health Care Authority  
4545 N. Lincoln Suite 124  
Oklahoma City, Oklahoma 73105  
**Oklahoma Health Care Authority Board Room**

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

- 1. Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

- 2. Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. McNeill, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. January 9, 2007 DUR Minutes – Vote
  - B. January 10, 2007 DUR Recommendations Memorandum

Items to be presented by Dr. Flannigan, Dr. McNeill, Chairman:

- 4. Update on DUR/MCAU Program – See Appendix B.**
  - A. Retrospective Drug Utilization Review for October 2007
  - B. Retrospective Drug Utilization Review Response for July 2007
  - C. Medication Coverage Activity Audit for January 2008
  - D. Help Desk Activity Audit for January 2008

Items to be presented by Dr. Gorman, Dr. McNeill, Chairman

- 5. 60 Day Notice to Prior Authorize Narcotic Analgesics – See Appendix C.**
  - A. Utilization Review
  - B. COP Recommendations
  - C. Potential Savings

Items to be presented by Dr. Chonlahan, Dr. McNeill, Chairman:

6. **30 Day Notice to Prior Authorize Combigan™ – See Appendix D.**
  - A. Product Summary
  - B. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. McNeill, Chairman

7. **Beta Blockers Utilization Review – See Appendix E.**
  - A. Product Summary
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Flannigan, Dr. McNeill, Chairman

8. **Erythropoiesis-Stimulating Agents Utilization Review – See Appendix F.**
  - A. Product Summary
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Browning, Dr. McNeill, Chairman

9. **Action Item: Annual Review of Insomnia Products – See Appendix G.**
  - A. Current PA Criteria
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Patel, Dr. McNeill, Chairman

10. **Action Item: Annual Review of Glumetza™ and Fortamet® – See Appendix H.**
  - A. Current PA Criteria
  - B. Utilization Review
  - C. COP Recommendations

11. **FDA and DEA Updates – See Appendix I.**

12. **Future Business**
  - A. FY07 Annual Review (Presented in March 2008)
  - B. Osteoporosis Utilization Review
  - C. Oral Allergy Follow-Up
  - D. Non-Hypnotic Benzodiazepine Review
  - E. Nasal Allergy PBPA Review
  - F. New Product Reviews